Alterations at MEK1/2 level: MEK2 mutations such as MEK2C125S and MEK2Q60P have been detected at higher frequencies in D/T combination therapy-resistant melanoma of patients than in BRAFi- or MEKi-monotherapy-resistant tumors [39,40]. This evidence concerns the gene MAP2K1 and melanoma.